https://cd3.be/rewind-therapeutics-secures-15-2-million-euro-to-develop-novel-remyelination-therapies-for-ms/
Rewind Therapeutics secures 15.2 million euro to develop novel remyelination therapies for MS - CD3
rewindtherapeuticssecuresmillioneuro
https://www.fondation-charcot.org/en/actualites/mot-cle-du-futur-remyelinisation-reparation-myeline
Key word of the future: remyelination — Belgian Charcot Foundation
Until now, all research has been aimed at curbing the disease.
key wordof thefutureremyelinationbelgian
https://multiplesclerosisnewstoday.com/2017/05/02/ms-remyelination-therapy-opicinumab-fails-phase2-trial-biogen-wont-give-up/
MS Remyelination Therapy Opicinumab Fails in Phase 2 Trial, But Biogen Won't Give Up
Feb 12, 2024 - Read about how a failed trial is not the end for the MS remyelination agent opicinumab, as researchers observed disability improvements in certain groups.
in phasegive upremyelinationtherapyopicinumab